| Autor: |
Lonial, S. Dimopoulos, M. Palumbo, A. White, D. Grosicki, S. Spicka, I. Walter-Croneck, A. Moreau, P. Mateos, M.-V. Magen, H. Belch, A. Reece, D. Beksac, M. Spencer, A. Oakervee, H. Orlowski, R.Z. Taniwaki, M. Röllig, C. Einsele, H. Wu, K.L. Singhal, A. San-Miguel, J. Matsumoto, M. Katz, J. Bleickardt, E. Poulart, V. Anderson, K.C. Richardson, P. ELOQUENT-2 Investigators |
| Jazyk: |
angličtina |
| Rok vydání: |
2015 |
| Popis: |
Background: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. Methods: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. Results: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
